Various preclinical models have been developed to clarify the pathophysiology of prostate
cancer (PCa). Traditional PCa cell lines from clinical metastatic lesions, as exemplified by …

Ribosomes are nanomachines essential for protein production in all living cells. Ribosome
synthesis increases in cancer cells to cope with a rise in protein synthesis and sustain …

Neuroendocrine (NE) prostate cancer (NEPC) is a lethal subtype of castration-resistant
prostate cancer (PCa) arising either de novo or from transdifferentiated prostate …

Prostate cancer is the second most common malignancy in men and androgen deprivation
therapy is the first‐line therapy. However, most cases will eventually develop castration …

Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish
a significant resource of patient-derived xenografts (PDXs) of prostate cancer for rapid and …

Prostate cancer is the most frequent nonskin cancer and second most common cause of
cancer-related deaths in man. Prostate cancer is a clinically heterogeneous disease with …

Long thought to be too big and too ubiquitous to fail, we now know that human cells can fail
to make sufficient amounts of ribosomes, causing a number of diseases collectively known …

With advances in the discovery of the clinical and molecular landscapes of prostate cancer
(PCa), implementation of precision medicine-guided therapeutic testing in the clinic has …

In the search for drugs to effectively treat cancer, the last 10 years have seen a resurgence
of interest in targeting ribosome biogenesis. CX-5461 is a potential inhibitor of ribosomal …

FOXA family proteins act as pioneer factors by remodeling compact chromatin structures.
FOXA1 is crucial for the chromatin binding of the androgen receptor (AR) in both normal …